These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 21268053)

  • 1. A stochastic multicriteria model for evidence-based decision making in drug benefit-risk analysis.
    Tervonen T; van Valkenhoef G; Buskens E; Hillege HL; Postmus D
    Stat Med; 2011 May; 30(12):1419-28. PubMed ID: 21268053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicriteria benefit-risk assessment using network meta-analysis.
    van Valkenhoef G; Tervonen T; Zhao J; de Brock B; Hillege HL; Postmus D
    J Clin Epidemiol; 2012 Apr; 65(4):394-403. PubMed ID: 22197518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A quantitative approach to benefit-risk assessment of medicines - part 1: the development of a new model using multi-criteria decision analysis.
    Mussen F; Salek S; Walker S
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16 Suppl 1():S2-S15. PubMed ID: 17546573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multiattribute model for evaluating the benefit-risk profiles of treatment alternatives.
    Felli JC; Noel RA; Cavazzoni PA
    Med Decis Making; 2009; 29(1):104-15. PubMed ID: 18812582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two approaches to incorporate clinical data uncertainty into multiple criteria decision analysis for benefit-risk assessment of medicinal products.
    Wen S; Zhang L; Yang B
    Value Health; 2014 Jul; 17(5):619-28. PubMed ID: 25128056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical aspects in comparative benefit-risk assessment: challenges and opportunities for pharmaceutical statisticians.
    Quartey G; Wang J
    Pharm Stat; 2012; 11(1):82-5. PubMed ID: 21997832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antidepressants: controversies about their efficacy in depression, their effect on suicidality and their place in a complex psychiatric treatment approach.
    Möller HJ
    World J Biol Psychiatry; 2009; 10(3):180-95. PubMed ID: 19575335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A quantitative approach to benefit-risk assessment of medicines - part 2: the practical application of a new model.
    Mussen F; Salek S; Walker S; Phillips L
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16 Suppl 1():S16-41. PubMed ID: 17546574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comprehensive approach to benefit-risk assessment in drug development.
    Sarac SB; Rasmussen CH; Rasmussen MA; Hallgreen CE; Søeborg T; Colding-Jørgensen M; Christensen PK; Thirstrup S; Mosekilde E
    Basic Clin Pharmacol Toxicol; 2012 Jul; 111(1):65-72. PubMed ID: 22356197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A simple way to unify multicriteria decision analysis (MCDA) and stochastic multicriteria acceptability analysis (SMAA) using a Dirichlet distribution in benefit-risk assessment.
    Saint-Hilary G; Cadour S; Robert V; Gasparini M
    Biom J; 2017 May; 59(3):567-578. PubMed ID: 28187230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coastal zone management with stochastic multi-criteria analysis.
    Félix A; Baquerizo A; Santiago JM; Losada MA
    J Environ Manage; 2012 Dec; 112():252-66. PubMed ID: 22940123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing therapeutic benefit and risk.
    Meyboom RH; Egberts AC
    Therapie; 1999; 54(1):29-34. PubMed ID: 10216419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients.
    Nemeroff CB; Thase ME;
    J Psychiatr Res; 2007; 41(3-4):351-9. PubMed ID: 16165158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling the value for money of changing clinical practice change: a stochastic application in diabetes care.
    Hoomans T; Abrams KR; Ament AJ; Evers SM; Severens JL
    Med Care; 2009 Oct; 47(10):1053-61. PubMed ID: 19648827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decision-making in priority setting for medicines--a review of empirical studies.
    Vuorenkoski L; Toiviainen H; Hemminki E
    Health Policy; 2008 Apr; 86(1):1-9. PubMed ID: 17950484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of scientific evidence of risks and benefits in determining risk management policies for medications.
    Andrews E; Dombeck M
    Pharmacoepidemiol Drug Saf; 2004 Sep; 13(9):599-608. PubMed ID: 15362082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: a cost-effectiveness study of nefazodone.
    Anton SF; Revicki DA
    Psychopharmacol Bull; 1995; 31(2):249-58. PubMed ID: 7491376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining the cost of reducing uncertainty with the selection of risk assessment models for remediation decision of site contamination.
    Chen YC; Ma HW
    J Hazard Mater; 2007 Mar; 141(1):17-26. PubMed ID: 16926066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.